ArticleOman medical journal2025
Clinical Features and Comparative Treatment Outcomes of Atomoxetine and Methylphenidate in Omani Adults with ADHD.
Article in Oman medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Association Between Job-Seeking & Adult Attention Deficient Hyperactivity Disorder Among Working-Age Individuals in Oman: A Retrospective Study from the National Clinical Service for Adult ADHD in Oman.Behavioral sciences (Basel, Switzerland) · 2026Article
- Diagnosis and Prescribing Patterns of Adult Attention-Deficit Hyperactivity Disorder in a Tertiary Care Hospital in the United Arab Emirates: A Retrospective Study.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the clinical presentation and treatment outcomes in Omani adults diagnosed with attention-deficit hyperactivity disorder (ADHD), with a focus on the efficacy of atomoxetine and methylphenidate in reducing symptoms, and identify clinical predictors of treatment response. Methods: This prospective study enrolled Omani adults with ADHD receiving treatment at Sultan Qaboos University Hospital, Oman. Data on sociodemographic and clinical history were collected. Treatment response was quantified using the Clinical Global Impressions-Improvement (CGI-I) scale, after three months of initiating treatment. Statistical analysis used independent chi-square tests and t-tests, with a significance threshold set at p < 0.05. Results: Among 171 participants, 60.8% were male. The majority (80.7%) received methylphenidate, while the others (19.3%) received atomoxetine. Inattentive subtype of ADHD (66.1%) was the most common, followed by combined hyperactivity and inattention (24.0%). Most (72.5%) patients had at least one comorbidity. After three months, 83.6% of the patients showed significant improvement on the Clinical Global Impressions-Improvement scale. Response rate for methylphenidate (84.8%) was higher than for atomoxetine (78.8%). Significant predictors of treatment response were male sex (odds ratio = 2.42, 95% CI: 1.00-5.71; p = 0.044) and absence of a family history of ADHD (odds ratio = 2.93, 95% CI: 1.18-7.28; p = 0.020). Conclusions: Both atomoxetine and methylphenidate were effective in treating adult ADHD, but methylphenidate showed a higher response rate. Male sex and the absence of a family history of ADHD were associated with greater response to treatment. These factors may serve as clinical indicators for tailoring pharmacological treatment decisions for individual adult ADHD patients in Oman.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.